Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART22 in r/r B-NHL
NCT05106946Phase 1Unknown
- Sponsor
- Fundamenta Therapeutics Inc.
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ThisCART22 cells in non-Hodgkin lymphoma (NHL), sponsored by Fundamenta Therapeutics Inc. Primary endpoint: Treatment related adverse events at 90 days. Status: unknown.
02
Drugs
ThisCART22 cells
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05106946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05106946.